Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...

Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...

Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...

Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (WBAG:HOLX) from Outperform to Market Perform. There are 1,442 funds or institutions reporting ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...